Development of generic gliclazide 60 mg modified release tablets using central composite design
A modified release gliclazide 60 mg tablet using Methocel® K100 Premium LV DC2 as a drug retaining polymer was prepared by direct compression. Central composite design was adopted for formulation optimization. The two independent formulation variables included the amount of Methocel® K100 LV DC2...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
College of Pharmacists of Buenos Aires Province, Argentina
2015
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/44848/1/Latin_American_Journal_of_Pharmacy_34_8_page_1516.pdf http://irep.iium.edu.my/44848/ http://www.latamjpharm.org/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A modified release gliclazide 60 mg tablet using Methocel® K100 Premium LV DC2 as a
drug retaining polymer was prepared by direct compression. Central composite design was adopted for
formulation optimization. The two independent formulation variables included the amount of Methocel®
K100 LV DC2 and Maltrin® M150, whereas the response variables were cumulative % drug release in 1,
2, 4, 8, and 12 h. Drug release data were fitted to various mathematical models for describing the release
mechanism from tablets. The effect of polymer and maltodextrin content on gliclazide release at different
time points were statistically evaluated by applying one-way ANOVA at 0.05. Four more formulas were
prepared to evaluate the prediction ability of the model. All the formulations showed a high correlation
coefficient (r2) with zero order and Korsmeyer-Peppas release mechanism. The actual cumulative % drug
release versus predicted of the evaluation formulations showed good model prediction with high similarity
(86-98) and low difference factors (1-3). |
|---|